Business
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
NEW BRUNSWICK, N.J., October 14, 2025--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. "Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson
About this update from Johnson & Johnson
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2404,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/be567f2c8c8518d639dff3088cbc6351"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/01ifxYLn.sbTwh_TWMK27g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/be567f2c8c8518d639dff3088cbc6351","width":960,"height":89},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/nEeT0lahfL6s3LTYd2MnOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yMjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/be567f2c8c8518d639dff3088cbc6351","width":1200,"height":112}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%*","length":139,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80","length":87,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump","length":354,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirms full year adjusted EPS4 guidance of $10.85 at the midpoint, absorbing higher tax costs","length":194,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":774,"olType":false},{"type":"text","content":"NEW BRUNSWICK, N.J., October 14, 2025--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. "Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "With a sharpened focus on the six pr...